Digest Network Come funziona
Network
/
Società
Ce
Non verificato

Celea Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

4 comunicati stampa

Guarda tutti i comunicati
29/10/2026
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
Fonte
Celea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
30/09/2026
Industria
Eventi
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Celea Therapeutics Presents SURPASS-IPF Phase 3 Trial Design and Statistical Considerations for Evaluating Clinical Trials in Idiopathic Pulmonary Fibrosis at the IPF Summit 2026
Fonte
Celea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
25/08/2026
Eventi
Industria
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress
Fonte
Celea Therapeutics, Inc.
Emittente
Business Wire
1.00
0
13/07/2026
Salute
Igiene alimentare
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Fonte
Celea Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0